Ghayas Issa

Leukemia Physician at MD Anderson. Research in AML, CML, other leukemias if it's the right genotype. Views expressed here are my own.

[Ghayas Issa @GhayasIssa]

Surreal to play a role in this relay race. Below proof that menin inhibition works. A new targeted therapy in leukemia published @Nature
https://t.co/SQQwgh6GzV @MDAndersonNews

[The Cancer Letter @TheCancerLetter]

Menin inhibitors emerge as new treatment for advanced AML. Guest editorial by Ghayas Issa (@GhayasIssa, @MDAndersonNews).
https://t.co/2m0swajbbf

[UT MD Anderson @UTMDAnderson]

"Our research confirmed the significant benefits and efficacy of this therapy for both adult and pediatric patients," says Dr. Ghayas Issa.

@US_FDA has approved revumenib for some patients with relapsed or refractory acute leukemia: https://t.co/NywVWKNzPS @GhayasIssa #EndCancer

[Ghayas Issa @GhayasIssa]

@JZarkaMD @MDAndersonNews Thanks Jabra - how about you come back to work on this? :)

[Ghayas Issa @GhayasIssa]

@TalhaBadarMD Thank you

[Ghayas Issa @GhayasIssa]

Menin inhibition is a standard of care! FDA approval of revumenib!! So happy to see that the benefit witnessed in patients on study is leading to a medicine to all who need it. Ready to forj ahead with more to come! ;)

[Ghayas Issa @GhayasIssa]

@Torsadepointles Thank you

[Ghayas Issa @GhayasIssa]

@LeukDocJZ Thx Josh!

[Ghayas Issa @GhayasIssa]

@CuglievanBranko Thank you partner

[Ghayas Issa @GhayasIssa]

@timheff5 Thanks Tim! Hope to team up with you for more

[Ghayas Issa @GhayasIssa]

@HindRafei Thanks Hind!

[Ghayas Issa @GhayasIssa]

@kchenken Thanks Ken!

[Ghayas Issa @GhayasIssa]

@matilde_boada Thank you!

[Ghayas Issa @GhayasIssa]

@IrenemGhobrial Thanks :)

[Ghayas Issa @GhayasIssa]

@zucenka Thanks Andrius! Hope to catch up at ASH

[Ghayas Issa @GhayasIssa]

@SamahNd Thank you!

[Ghayas Issa @GhayasIssa]

@ABidikianMD Thanks Aram!

[Ghayas Issa @GhayasIssa]

@may_daher @MDAndersonNews Thanks May!

[Ghayas Issa @GhayasIssa]

@WeraBorek Thank you

[Ghayas Issa @GhayasIssa]

The first BTC trial to target AML MRD with combination of menin and BCL2 inhibition is now open! Huge team effort and more exciting trials for MRD to come. Goal is to better measure, understand and treat MRD

[𝗕𝗿𝗲𝗮𝗸 𝙏𝙝𝙧𝙤𝙪𝙜𝙝 𝗖𝗮𝗻𝗰𝗲𝗿 @break_cancer]

We’ve enrolled the first patient in a phase 2 clinical trial targeting minimal residual disease in #AML, hoping to prevent relapse by eliminating lingering cancer cells. #RadicalCollaboration
@GhayasIssa @MDAndersonNews

[Ghayas Issa @GhayasIssa]

@timheff5 Thanks Tim

[Ghayas Issa @GhayasIssa]

@LeukDocJZ Thanks Josh!